Patents Issued in February 25, 2020
-
Patent number: 10570164Abstract: The present invention relates generally to steviol glycosides, as well as compositions comprising such steviol glycosides. The present invention further extends to methods of preparing and purifying such steviol glycosides and methods for enhancing the flavor or sweetness of consumables using these steviol glycosides and compositions. The present invention extends to consumables comprising steviol glycosides, where the such steviol glycosides are present in a concentration at or below their sweetness recognition threshold, and wherein such steviol glycosides enhance the sweetness of the consumable.Type: GrantFiled: March 18, 2014Date of Patent: February 25, 2020Assignees: The Coca-Cola Company, PureCircle SDN BHDInventors: Indra Prakash, Venkata Sai Prakash Chaturvedula, Juvenal Higiro, Avetik Markosyan
-
Patent number: 10570165Abstract: Compositions including derivatives of spinosyns and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include those functionalized on the C-5,6 double bond to provide an aziridine ring system. The method produces spinosyn derivatives that exhibit activity towards insects, arachnids, and nematodes and are useful in the agricultural and animal health markets.Type: GrantFiled: January 3, 2018Date of Patent: February 25, 2020Assignee: AgriMetis, LLCInventor: Andrew A. Calabrese
-
Patent number: 10570166Abstract: Compositions including derivatives of spinosyns and methods for the production of derivatives of spinosyns are provided. The spinosyn derivatives described herein include spinosyn derivatives functionalized on the C5-C6 double bond of the spinosyn. The method produces spinosyn derivatives that exhibit activity towards insects, arachnids, and nematodes and are useful in the agricultural and animal health markets.Type: GrantFiled: September 1, 2016Date of Patent: February 25, 2020Assignee: AgriMetis, LLCInventor: Andrew Calabrese
-
Patent number: 10570167Abstract: The invention relates to novel heterocyclic compounds and pharmaceutical preparations thereof. The invention further relates to methods of treating or preventing cancer using the novel heterocyclic compounds of the invention.Type: GrantFiled: December 21, 2017Date of Patent: February 25, 2020Assignee: Calithera Biosciences, Inc.Inventors: Roland J. Billedeau, Jim Li, Lijing Chen
-
Patent number: 10570168Abstract: Disclosed are chemical compounds, the compounds for use in a method of treatment, particularly in a method of prophylaxis or treatment for cancer, a process for preparation of the compounds and pharmaceutical compositions comprising the compounds. The compounds may, in particular, be useful in the treatment of leukaemia, lymphoma and/or solid tumours in homo sapiens. The compounds are derivatives of cordycepin (3?-deoxyadenosine) having a 2? and/or 5?-amino-acid ester phosphoramidate moiety.Type: GrantFiled: November 27, 2015Date of Patent: February 25, 2020Assignee: Nucana plcInventors: Hugh Griffith, Christopher McGuigan, Valentina Ferrari, Michaela Serpi, Carmen Jimenez Antunez
-
Patent number: 10570169Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the gomeric compounds are conjugated to N-Acetylgalactosamine or to N-Acetylgalactosamine analogues.Type: GrantFiled: May 21, 2015Date of Patent: February 25, 2020Assignee: Ionis Pharmaceuticals, Inc.Inventors: Punit P. Seth, Thazha P. Prakash, Michael T. Migawa, Eric E. Swayze
-
Patent number: 10570171Abstract: Novel compositions for removing impurities such as, protein aggregates, from a sample containing a protein of interest, e.g., an antibody. Such compositions can be used prior to the virus filtration step during protein purification, to remove aggregates and protect the virus filter from fouling, therefore improving virus filter capacity. A porous solid support including a co-polymer having at least two monomers, wherein at least one of the monomers comprises acrylamide and at least a second monomer comprises a hydrophobic binding group, where the solid support selectively binds protein aggregates, thereby to separate the monomeric protein of interest from the protein aggregates. The method can be performed under neutral to high pH and high conductivity conditions.Type: GrantFiled: March 14, 2018Date of Patent: February 25, 2020Assignee: EMD Millipore CorporationInventors: Mikhail Kozlov, William Cataldo, Jeffrey Caron
-
Patent number: 10570172Abstract: Self assembling peptides in combination with infectious and non-infectious proteins as inhibitors and diagnostic tools in transmissible spongiform encephalopathies and amyloid producing neuorodegenerative diseases are described herein.Type: GrantFiled: September 30, 2009Date of Patent: February 25, 2020Assignee: The United States of America, as represented by the Secretary of AgricultureInventor: Robert M. Hnasko
-
Patent number: 10570173Abstract: Compounds useful as contrast agents in image-guided surgery are provided. The compounds comprise a latent cationic lysosomotropic fragment that is detectable upon cleavage by lysosomal proteases within treated tissues, particularly within tumors and other diseased tissues. Also provided are compositions comprising the compounds and methods for using the compounds, for example in dynamically monitoring protease activity in vivo during image-guided tumor resection surgery.Type: GrantFiled: January 22, 2016Date of Patent: February 25, 2020Assignee: The Board of Trustees of the Leland Stanford Junior UniversityInventors: Matthew S. Bogyo, Martijn Verdoes, Leslie Ofori, Nimali P. Withana
-
Patent number: 10570174Abstract: Synthetic peptides containing chemical modifications having anti-tumor properties are provided. Further provided are pharmaceutical compositions including the peptides and use thereof for treating proliferative and neoplastic diseases such as cancer.Type: GrantFiled: February 7, 2016Date of Patent: February 25, 2020Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem Ltd.Inventor: Uri Wormser
-
Patent number: 10570175Abstract: The present invention relates to peptides, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated cytotoxic T cell (CTL) peptide epitopes, alone or in combination with other tumor-associated peptides that serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses. The present invention relates to several novel peptide sequences and their variants derived from HLA class I and HLA class II molecules of human tumor cells that can be used in vaccine compositions for eliciting anti-tumor immune responses.Type: GrantFiled: May 24, 2019Date of Patent: February 25, 2020Assignee: Immatics Biotechnologies GmbHInventors: Juliane Walz, Daniel Johannes Kowalewski, Hans-Georg Rammensee, Stefan Stevanovic
-
Patent number: 10570176Abstract: The present invention relates to the field of polypeptide medicine, and relates to polypeptides against hepatitis B virus X Protein and uses thereof. Specifically, the present invention relates to polypeptides comprising D-amino acids, which have a function of inhibiting hepatitis B virus X protein, and inhibit HBx activities, inhibit replication of hepatitis B virus DNA and expression of related antigens (e.g., HBeAg) at molecular level, cellular level and animal level, and further inhibit hepatitis and hepatic cirrhosis caused by hepatitis B virus infection and liver cancer that occurs on the basis of hepatic cirrhosis. The polypeptides can be widely used in the prevention and treatment of liver diseases after hepatitis B infection, including hepatitis, hepatic cirrhosis, and liver cancer.Type: GrantFiled: October 16, 2015Date of Patent: February 25, 2020Assignee: Tianjin TOPTECH Bio-Science & Technology Co., Ltd.Inventors: Xiaodong Zhang, Lihong Ye
-
Patent number: 10570177Abstract: Herein provided are peptide inhibitors and methods for treating polyglutamine (polyQ) diseases. Also disclosed are related compositions and kits for therapeutic use in the treatment of polyQ diseases.Type: GrantFiled: February 13, 2018Date of Patent: February 25, 2020Assignees: The Chinese University of Hong Kong, University of CopenhagenInventors: Ho Yin Edwin Chan, Knud J. Jensen, Jacky Chi Ki Ngo, Kasper K Sorensen, Qian Zhang, Zhong Zuo
-
Patent number: 10570178Abstract: Disclosed herein is a selective delivery molecule comprising: (a) an acidic sequence (portion A) which is effective to inhibit or prevent the uptake into cells or tissue retention, (b) a molecular transport or retention sequence (portion B), and (c) a linker between portion A and portion B, and (d) at least one cargo moiety.Type: GrantFiled: December 20, 2018Date of Patent: February 25, 2020Assignee: AVELAS BIOSCIENCES, INC.Inventors: Jesus Gonzalez, Junjie Liu
-
Patent number: 10570179Abstract: In one aspect, the invention relates to substituted urea depsipeptide analogs, derivatives thereof, and related compounds, which are useful as activators the ClpP endopeptidease; synthesis methods for making the compounds; pharmaceutical compositions comprising the compounds; and methods of treating infectious disease using the compounds and compositions. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention.Type: GrantFiled: September 1, 2017Date of Patent: February 25, 2020Assignee: St. Jude Children's Research HospitalInventors: Richard E. Lee, Ying Zhao
-
Patent number: 10570180Abstract: The present invention provides an agent, or a composition containing an agent, for use in treating or preventing a bacterial infection in a subject, wherein said agent comprises: (i) an oligopeptidic compound comprising a PCNA interacting motif and a domain that facilitates the cellular uptake of said compound, wherein the PCNA interacting motif is X1X2X3X4X5X6 (SEQ ID NO: 1) and wherein: X1 is a basic amino acid; X2 is an aromatic amino acid; X3 is an aromatic amino acid or a hydrophobic amino acid that has an R group comprising at least three carbon atoms; X4 is an uncharged amino acid other than an aromatic amino acid, Glycine (G) and Proline (P); X5 is any amino acid other than an acidic amino acid or an aromatic amino acid; and X6 is any amino acid other than an acidic amino acid or an aromatic amino acid, preferably a basic amino acid or Proline (P), wherein when X3 is not an aromatic amino acid, X5 is not lysine (K) and X6 is a basic amino acid or Proline (P); or (ii) a nucleic acid molecule comprisingType: GrantFiled: May 6, 2016Date of Patent: February 25, 2020Assignee: NORWEGIAN UNIVERSITY OF SCIENCE AND TECHNOLOGY (NTNU)Inventors: Marit Otterlei, Siri Bachke
-
Patent number: 10570181Abstract: A synthetic multiphase product comprising BsIA is presented. Methods of producing a synthetic multiphase product comprising BsIA, and applications of BsIA in synthetic multiphase products are also presented.Type: GrantFiled: August 18, 2015Date of Patent: February 25, 2020Assignee: THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGHInventors: Cait MacPhee, Nicola Stanley-Wall, Keith Bromley, Ryan Morris, Laura Hobley
-
Patent number: 10570182Abstract: The subject invention concerns Bacillus thuringiensis modified Cry1Ca insecticidal toxins and the polynucleotide sequences which encode these toxins. Uses in transgenic plants are described as are methods for protecting crops from insect pest damage.Type: GrantFiled: December 16, 2015Date of Patent: February 25, 2020Assignee: DOW AGROSCIENCES LLCInventors: Joel J. Sheets, Kenneth Narva, Thomas Meade, Timothy D. Hey, Sek Yee Tan, Audrey Jane Etter, Todd P. Glancy, Janna Mai Armstrong, Tristan E. Coram, Krishna M. Madduri, James E. King, Ryan M. Lee, Gaofeng Lin, Jianquan Li
-
Patent number: 10570183Abstract: The present disclosure describes a new native peptide designated herein as Dwarf Open Reading Frame, or DWORF. This peptide enhances the apparent activity of the SERCA pump, is positively inotropic and lusitropic, and therefore is provided as a therapeutic agent for disorders characterized by cytosolic calcium overload.Type: GrantFiled: April 19, 2017Date of Patent: February 25, 2020Assignee: The Board of Regents of the University of Texas SystemInventors: Eric N. Olson, Rhonda S. Bassel-Duby, Catherine A. Makarewich, Benjamin R. Nelson
-
Patent number: 10570184Abstract: The present invention relates to novel glucagon derivatives which are GLP-1/glucagon receptor co-agonists, and to the use of the glucagon derivatives in medicine, such as in the treatment of diabetes, obesity and related diseases and conditions.Type: GrantFiled: June 3, 2015Date of Patent: February 25, 2020Assignee: Novo Nordisk A/SInventors: Ulrich Sensfuss, Jesper F. Lau, Thomas Kruse
-
Patent number: 10570185Abstract: Provided herein are epitopes and mimotopes thereof useful in the diagnosis and treatment of type 1 diabetes (T1D), as well as antibodies recognizing such epitopes, and diagnostics, therapeutics, kits, and methods of use thereof.Type: GrantFiled: May 11, 2016Date of Patent: February 25, 2020Assignee: NORTHWESTERN UNIVERSITYInventors: Jing Jin, Xunrong Luo, Grazia Aleppo
-
Patent number: 10570186Abstract: Chimeric antigen receptor (CAR) constructs are provided that are able to selectively bind to specific protein complexes, such as HER 1/HER3 heterodimer receptors. CAR T-cells comprising these constructs can be used to safely and efficiently target cancer cells expressing specific protein complexes.Type: GrantFiled: November 4, 2015Date of Patent: February 25, 2020Assignee: BOARD OF REGENTS, THE UNIVERSITY OF TEXAS SYSTEMInventors: Laurence J. N. Cooper, Bipulendu Jena
-
Patent number: 10570187Abstract: Disclosed are soluble hybrid Fc? receptor (Fc?R) polypeptide compositions and related methods of using such polypeptides to treat IgG-mediated and immune complex-mediated inflammation. Also disclosed are related compositions and methods for producing the soluble hybrid Fc?R polypeptides.Type: GrantFiled: April 21, 2017Date of Patent: February 25, 2020Assignee: ZymoGenetics, Inc.Inventors: Carl W. Birks, Brian A. Fox, Mark W. Rixon, Jeff L. Ellsworth
-
Patent number: 10570188Abstract: Herein is reported a method for the production of a polypeptide that is biologically active as n-mer comprising a nucleic acid encoding a fusion polypeptide according to the following formula (Bn-CSo-Is-CSp-FC-CSq-ItCSr-Bm)u, wherein B denotes a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region, FC denotes a heavy chain Fc-region polypeptide, CS denotes a cleavage site, and I denotes an intervening amino acid sequence, wherein FC does not substantially bind to an Fc-receptor, recovering the fusion polypeptide from the cell or the cultivation medium, optionally cleaving the fusion polypeptide with a protease, and thereby producing a polypeptide that is biologically active as n-mer and forms non-defined aggregates/multimers upon expression in the absence of a fused Fc-region.Type: GrantFiled: May 9, 2017Date of Patent: February 25, 2020Assignee: Hoffmann-La Roche Inc.Inventors: Johannes Auer, Martin Bader, Stefan Dengl, Stefan Lorenz, Stefan Seeber
-
Patent number: 10570189Abstract: The present disclosure provides muteins of FVIII to which a biocompatible polymer may be attached to increase the circulatory half-life of the muteins, as well as conjugates of such muteins and biocompatible polymers.Type: GrantFiled: March 4, 2015Date of Patent: February 25, 2020Assignee: PFIZER INC.Inventors: James Apgar, Debra Pittman, Mark Stahl, Laura Lin, Justin Cohen
-
Patent number: 10570190Abstract: Compositions are provided, which can be used as frameworks for the creation of very stable and soluble single-chain Fv antibody fragments. These frameworks have been selected for intracellular performance and are thus ideally suited for the creation of scFv antibody fragments or scFv antibody libraries for applications where stability and solubility are limiting factors for the performance of antibody fragments, such as in the reducing environment of a cell. Such frameworks can also be used to identify highly conserved residues and consensus sequences which demonstrate enhanced solubility and stability.Type: GrantFiled: October 30, 2018Date of Patent: February 25, 2020Assignee: Novartis AGInventors: Kathrin Tissot, Stefan Ewert, Adrian Auf Der Maur, Alcide Barberis, Dominik Escher
-
Patent number: 10570191Abstract: This disclosure provides a multimeric human immunodeficiency virus (HIV) protein binding molecule, e.g., an dimeric IgA or a pentameric or hexameric IgM binding molecule, comprising at least two bivalent binding units, or variants or fragments thereof, each comprising at least two antibody heavy chain constant regions or fragments thereof, wherein each heavy chain constant region or fragment thereof is associated with an HIV antigen binding domain. Also provided are compositions comprising the multimeric binding molecules, polynucleotides encoding the multimeric binding molecules, and methods to make and use the multimeric binding molecules.Type: GrantFiled: April 15, 2016Date of Patent: February 25, 2020Assignee: IGM Biosciences, Inc.Inventors: Bruce Alan Keyt, Dan T. Stinchcomb, Ole A. Olsen
-
Patent number: 10570192Abstract: The invention provides anti-wall teichoic acid antibodies and antibiotic conjugates thereof, and methods of using the same.Type: GrantFiled: September 28, 2017Date of Patent: February 25, 2020Assignee: Genentech, Inc.Inventors: Eric J. Brown, Martine Darwish, John Flygare, Wouter Hazenbos, Byoung Chul Lee, Sophie M. Lehar, Sanjeev Mariathasan, John Hiroshi Morisaki, Thomas H. Pillow, Leanna Staben, Richard Vandlen, Klaus Koefoed, Magnus Strandh, Peter S. Andersen
-
Patent number: 10570193Abstract: Binding agents able to disrupt bacterial biofilms of diverse origin are described, including monoclonal antibodies suitable for administration to a selected species, and antibody mimics including aptamer nucleic acids. Methods to prevent formation of or to dissolve biofilms with these binding agents are also described. Immunogens for eliciting antibodies to disrupt biofilms are also described.Type: GrantFiled: November 5, 2018Date of Patent: February 25, 2020Assignee: Trellis Bioscience, LLCInventors: Lawrence M. Kauvar, Stefan Ryser, Angeles Estelles, Reyna J. Simon, Lauren Opremcak Bakaletz, Steven David Goodman
-
Patent number: 10570194Abstract: Compositions and methods of the present invention prevent, inhibit or reduce the toxic effects of proteins and toxins secreted from microbes. A method for neutralizing microbial protein products in a subject comprises administering a composition to the subject, said composition comprising plasma-derived IgM and optionally one or more excipients in a pharmaceutical carrier, wherein the composition is administered in an amount effective to neutralize the microbial protein products.Type: GrantFiled: May 17, 2016Date of Patent: February 25, 2020Assignee: GRIFOLS WORLDWIDE OPERATIONS LIMITEDInventors: Thomas Barnett, David A. Ross
-
Patent number: 10570195Abstract: An antibody or fragment thereof capable of binding to a neurotoxic tau protein. The neurotoxic tau protein includes a phosphorylation site at threonine residue 231 in AT180 domain of tau proteins and an amino acid substitution of proline residue 232 to glycine (P232G) in AT180 domain of tau proteins.Type: GrantFiled: March 11, 2019Date of Patent: February 25, 2020Inventor: Koorosh Shahpasand
-
Patent number: 10570196Abstract: The disclosure provides methods of treating tauopathies (e.g. Alzheimer's disease, Amyotrophic Lateral Sclerosis, Frontotemporal Dementia with Parkinsonism linked to chromosome 17, Pick's Disease, Progressive Supranuclear Palsy, Dementia Pugilistica, Down's Syndrome and others) by administering humanized antibodies. The disclosure also provides the anti-tau humanized antibodies that bind the N-terminal region of tau and also bind to pathological tau aggregates, conformational epitopes and peptides mimicking these epitopes (mimotopes).Type: GrantFiled: July 12, 2017Date of Patent: February 25, 2020Inventor: Anahit Ghochikyan
-
Patent number: 10570197Abstract: It is an object of the present invention to provide a method for producing a low-molecular-weight antibody such as a Fab-type antibody, using yeast as a host, wherein the method is able to produce the low-molecular-weight antibody with high productivity. According to the present invention, there is provided a gene comprising a nucleotide sequence encoding an amino acid or an amino acid sequence capable of increasing the secretion amount of a Fab-type antibody at the 3?-terminus of a nucleotide sequence encoding the amino acid sequence of the Fd chain or L chain of an antibody.Type: GrantFiled: October 23, 2015Date of Patent: February 25, 2020Assignee: KANEKA CORPORATIONInventor: Tozo Nishiyama
-
Patent number: 10570198Abstract: The invention provides antibodies that are modified to reduce aggregration propensity, and methods of producing such antibodies. The present invention also provides particularly stable and soluble scFv antibodies and Fab fragments specific for TNF, which comprise specific light chain and heavy chain sequences that are optimized for stability, solubility, in vitro and in vivo binding of TNF, and low immunogenicity. The nucleic acids, vectors and host cells for expression of the recombinant antibodies of the invention, methods for isolating them and the use of said antibodies in medicine are also disclosed.Type: GrantFiled: February 18, 2016Date of Patent: February 25, 2020Assignee: NOVARTIS AGInventors: Leonardo Jose Borras, David Urech
-
Patent number: 10570199Abstract: The present invention relates to a human anti-human IL-18 antibody which reacts with human interleukin-18 (human IL-18) and does not react with a K53A variant of human IL-18.Type: GrantFiled: November 18, 2013Date of Patent: February 25, 2020Assignee: KM Biologics Co., Ltd.Inventors: Hiroyuki Shimizu, Miyuki Matsumoto, Kenji Soejima, Masaharu Torikai, Toshihiro Nakashima
-
Patent number: 10570200Abstract: The present disclosure generally relates to methods and compositions for contraception. In some embodiments, vector based approaches for contraception are provided.Type: GrantFiled: January 31, 2014Date of Patent: February 25, 2020Assignee: California Institute of TechnologyInventors: Bruce A. Hay, Juan Li
-
Patent number: 10570201Abstract: Disclosed herein are anti-CD47 antibody molecules, their manufacture and use in treating disorders associated with CD47 expression, for example, certain hematological cancers and solid tumors.Type: GrantFiled: September 21, 2017Date of Patent: February 25, 2020Assignees: Erasmus University Medical Center, Surface Oncology, Inc.Inventors: Frank Grosveld, Scott Chappel, Jonathan Hill, Pamela M. Holland, Andrew Lake, Alison Paterson
-
Patent number: 10570202Abstract: The present disclosure describes combination therapies comprising an antagonist of Programmed Death 1 receptor (PD-1) and a VEGFR inhibitor, and the use of the combination therapies for the treatment of cancer, and in particular for treating cancers that express PD-L1.Type: GrantFiled: February 3, 2015Date of Patent: February 25, 2020Assignees: Pfizer Inc., Merck Sharpe & Dohme Corp.Inventors: Jean-Francois Andre Martini, Jamal Christo Tarazi, Rodolfo Fleury Perini, David J. Mauro
-
Patent number: 10570203Abstract: Provided herein are various embodiments relating to antibodies. Some of the embodiments include agonist antibodies that bind ICOS. Such antibodies can be used in methods to treat, for example, cancer.Type: GrantFiled: June 20, 2018Date of Patent: February 25, 2020Assignee: Jounce Therapeutics, Inc.Inventors: Stephen Sazinsky, Jennifer S. Michaelson, Sriram Sathyanarayanan, Kutlu Goksu Elpek
-
Patent number: 10570204Abstract: The present invention relates to methods of treating hematologic cancers using a combination of inhibitors of PD-1 or PD-L1 and TIM-3, LAG-3 or CTLA-4. In one embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of TIM-3. In another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of LAG-3. In yet another embodiment, an inhibitor of PD-1 or PD-L1 is administered in combination with an inhibitor of CTLA-4.Type: GrantFiled: September 25, 2014Date of Patent: February 25, 2020Assignees: The Medical College of Wisconsin, Inc., Novartis AGInventors: Bryon Duane Johnson, Robert Millman
-
Patent number: 10570205Abstract: The present invention provides compositions and methods relating to or derived from antigen binding proteins activate FGF21-mediated signaling. In embodiments, the antigen binding proteins specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4. In some embodiments the antigen binding proteins induce FGF21-like signaling. In some embodiments, an antigen binding protein is a fully human, humanized, or chimeric antibodies, binding fragments and derivatives of such antibodies, and polypeptides that specifically bind to (i) ?-Klotho; (ii) FGFR1c, FGFR2c, FGFR3c or FGFR4; or (iii) a complex comprising ?-Klotho and one of FGFR1c, FGFR2c, FGFR3c, and FGFR4.Type: GrantFiled: September 29, 2016Date of Patent: February 25, 2020Assignee: Amgen, Inc.Inventors: Shaw-Fen Sylvia Hu, Ian Nevin Foltz, Chadwick Terence King, Yang Li, Taruna Arora
-
Patent number: 10570206Abstract: The present invention relates in general to the field of TNF ligand family members. In more detail the present invention relates to polypeptides comprising at least three components A, each of which comprises the sequence of a TNF homology domain (THD) of a TNF ligand family member, or a functional derivative thereof, and comprising at least one component B consisting of a VL region and a VH region linked directly to each other with a linker sequence L which has a length of <12 amino acids. Furthermore, the present invention also relates to nucleic acids encoding such polypeptides and pharmaceutical compositions thereof.Type: GrantFiled: October 30, 2017Date of Patent: February 25, 2020Assignee: UNIVERSITAT STUTTGARTInventors: Klaus Pfizenmaier, Roland Kontermann, Martin Siegemund
-
Patent number: 10570207Abstract: Disclosed herein are non-myeloablative antibody-toxin conjugates and compositions that target cell surface markers, such as the CD34, CD45 or CD117 receptors, and related methods of their use to effectively conditioning a subject's tissues (e.g., bone marrow tissue) prior to engraftment or transplant. The compositions and methods disclosed herein may be used to condition a subject's tissues in advance of, for example, hematopoietic stem cell transplant and advantageously such compositions and methods do not cause the toxicities that are commonly associated with traditional conditioning methods.Type: GrantFiled: November 29, 2018Date of Patent: February 25, 2020Assignees: President and Fellows of Harvard College, The General Hospital Corporation, The Children's Medical Center CorporationInventors: David T. Scadden, Rahul Palchaudhuri, Derrick J. Rossi, Agnieszka D. Czechowicz
-
Patent number: 10570208Abstract: Described herein are methods and compositions for treating autoimmunity and inflammatory conditions without non-specific suppression of the host immune system. In particular, the anti-OX40L antibodies described herein are unique in that they not only inhibit the differentiation of inflammatory T cells but also promote the generation and function of regulatory T cells by inducing IL-10 and inhibiting TNF-? and by reducing aberrant Th2 cell responses. Furthermore, the methods and compositions described herein eliminate or reduce aberrant T follicular helper cell—(Tfh) responses that may contribute to the pathogenicity of autoimmune disease.Type: GrantFiled: December 5, 2018Date of Patent: February 25, 2020Assignee: Baylor Research InstituteInventors: Yong-Jun Liu, Sandra Zurawski, SangKon Oh, Shino Hanabuchi, Haruyuki Fujita, Hideki Ueno, Patrick Blanco, Hyemee Joo
-
Patent number: 10570209Abstract: The present invention provides binding molecules that specifically bind to GITR, e.g., human GITR (hGITR), on T cells and dendritic cells. Binding molecules of the invention are characterized by binding to hGITR with high affinity, in the presence of a stimulating agent, e.g., CD3, are agonistic, and abrogate the suppression of Teff cells by Treg cells. Various aspects of the invention relate to binding molecules, and pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such binding molecules. Methods of using a binding molecule of the invention to detect human GITR or to modulate human GITR activity, either in vitro or in vivo, are also encompassed by the invention.Type: GrantFiled: June 28, 2018Date of Patent: February 25, 2020Assignee: GITR, Inc.Inventors: L. Mary Smith, Grazyna Szymanska, Paul Ponath, Michael Rosenzweig, Jose F. Ponte
-
Patent number: 10570210Abstract: An isolated monoclonal antibody that specifically binds human CD40. A nucleic acid molecule encoding the antibody, an expression vector, a host cell and a method for expressing the antibody are also provided. The present invention further provides an immunoconjugate, a bispecific molecule, a chimeric antigen receptor, an oncolytic virus and a pharmaceutical composition comprising the antibody, as well as a treatment method using an anti-CD40 antibody of the invention.Type: GrantFiled: March 4, 2019Date of Patent: February 25, 2020Assignee: Beijing Mabworks Biotech Co.LtdInventors: Wenqi Hu, Jiangmei Li, Feng Li
-
Patent number: 10570211Abstract: Herein described are antibodies to epidermal growth factor receptor (EGFR) having an EGFR binding affinity that is sufficient to kill disease cells presenting EGFR at high density, but is insufficient for binding to normal cells. A therapeutic effect is thus achieved while avoiding adverse events that result from unintended binding to normal cells.Type: GrantFiled: January 20, 2012Date of Patent: February 25, 2020Assignees: GILEAD SCIENCES, INC., NATIONAL RESEARCH COUNCIL OF CANADAInventors: Ilia Alexandre Tikhomirov, Maria L. Jaramillo, Maureen D. O'Connor-McCourt, Traian Sulea, Renald Gilbert, Bruno Gaillet, Jason Baardsnes, Myriam Banville, Suzanne Grothe
-
Patent number: 10570212Abstract: The invention relates to novel benzodiazepine derivatives with antiproliferative activity and more specifically to novel benzodiazepine compounds of formula (I)-(VII). The invention also provides conjugates of the benzodiazepine compounds linked to a cell-binding agent. The invention further provides compositions and methods useful for inhibiting abnormal cell growth or treating a proliferative disorder in a mammal using the compounds or conjugates of the invention.Type: GrantFiled: November 30, 2018Date of Patent: February 25, 2020Assignee: IMMUNOGEN, INC.Inventors: Wei Li, Michael Louis Miller, Nathan Elliott Fishkin, Ravi V. J. Chari
-
Patent number: 10570213Abstract: The invention provides methods and compositions for treating cancer and for enhancing immune function in an individual having cancer. The methods comprise administering a PD-1 axis binding antagonist and a taxane.Type: GrantFiled: May 27, 2016Date of Patent: February 25, 2020Assignee: Genentech, Inc.Inventors: Jeong Kim, Jeanne Cheung
-
Patent number: 10570214Abstract: The invention provides chimeric antigen receptors (CARs) comprising an antigen binding domain of human antibody 139, an extracellular hinge domain, a transmembrane domain, and an intracellular domain T cell receptor signaling domain. Nucleic acids, recombinant expression vectors, host cells, populations of cells, antibodies, or antigen binding portions thereof, and pharmaceutical compositions relating to the CARs are disclosed. Methods of detecting the presence of cancer in a host and methods of treating or preventing cancer in a host are also disclosed.Type: GrantFiled: March 3, 2017Date of Patent: February 25, 2020Assignee: The United States of America, as represented by the Secretary, Department of Health and Human ServicesInventors: Richard A. Morgan, Steven A. Rosenberg